1. Home
  2. ELUT vs LEXX Comparison

ELUT vs LEXX Comparison

Compare ELUT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$1.16

Market Cap

23.3M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.66

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELUT
LEXX
Founded
2015
2004
Country
United States
Canada
Employees
N/A
7
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
16.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ELUT
LEXX
Price
$1.16
$0.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$1.50
AVG Volume (30 Days)
165.1K
168.8K
Earning Date
04-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
10.14
N/A
EPS
N/A
N/A
Revenue
$24,375,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.46
52 Week High
$3.46
$1.90

Technical Indicators

Market Signals
Indicator
ELUT
LEXX
Relative Strength Index (RSI) 62.73 47.12
Support Level $0.86 $0.58
Resistance Level $2.05 $0.83
Average True Range (ATR) 0.12 0.06
MACD 0.00 0.01
Stochastic Oscillator 68.04 64.52

Price Performance

Historical Comparison
ELUT
LEXX

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: